हिंदी
Chandigarh December 21, 2021
University Institute of Pharmaceutical Sciences, Panjab University has been granted First Australian Innovation Patent entitled “NANOPARTICLE HYDROGEL COMPOSITION FOR THE TREATMENT OF NEUROPATHIC PAIN.” This novel gel is developed for diabetic and cancer chemotherapy-induced neuropathic pain, which will target the dorsal root ganglion, the leading target site responsible for peripheral neuropathy and targeting of which will also block central effects. This gel being developed is one of a kind as it is patient compliant due to its once-a-day application and long-term impact with negligible side effects. To date, the therapy available for diabetic and cancer neuropathic pain includes drugs having a lot of side effects and no significant relief.
READ MORE :-Professor J. C. Anand Memorial Lecture held at PU
This technology has been invented by Dr Ranjana Bhandari and Dr Anurag Kuhad from University Institute of Pharmaceutical Sciences & Dr Jyoti K Paliwal, Director, Phaex Consulting, Gurgaon, Haryana, Ex-Director B. V. Patel PERD Centre, Ahmadabad, Ex- VP Wockhardt Ltd, Mumbai, and Ex-Director, Ranbaxy, Gurgaon, Haryana.
This technology is developed under financial assistance of Pfizer-IIT Delhi and DST-UT Chandigarh grant 2020. Patent filing assistance and finance were sanctioned by Professor Manu Sharma, Honorary Director, Centre for Industry Institute Partnership Programme (CIIPP), Panjab University, Chandigarh. Indian Patent Application has also been filed for this technology. This technology would be licensed out to the industry after its completion of clinical studies.
